Latest Administration News

Almonty Industries will voluntarily delist from the ASX by September 1, 2026, consolidating its trading on Nasdaq and Frankfurt amid strategic shifts in its market presence.

Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.

Virgin Australia Holdings (ASX:VGN) posted a 13.4% rise in underlying EBIT to $753 million for FY26, declaring a fully franked dividend of 7.6 cents per share, its first since relisting. The airline’s transformation program, fleet renewal, and operational resilience underpin its improved financial and customer metrics.

NobleOak Life delivered robust FY26 results with in-force premiums climbing 18% to $549.2 million and underlying NPAT up 15%, driven by strong market share gains and operational efficiency.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Bentley Capital Limited swung back to profitability in FY2026, posting a $255,000 net profit driven mainly by legal settlements and modest investment gains, reversing a prior loss of $878,000.

Revolution Private Credit Income Trust (ASX: REV) posted a 6.25% net return for its inaugural period, outperforming its benchmark, and executed an on-market buy-back worth $23 million.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Almasar Minerals Limited (ASX:AMK) is launching an IPO to fund early-stage exploration across five licences in Saudi Arabia’s Arabian Shield, targeting gold and copper mineralisation.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.